Sagimet Biosciences Inc.

06/10/2025 | Press release | Distributed by Public on 06/10/2025 15:17

Management Change/Compensation (Form 8-K)

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 6, 2025, Sagimet Biosciences Inc. (the "Company") entered into amended and restated executive employment agreements with certain of its executive officers pursuant to which certain severance provisions were modified to align with market practices, including a second amended and restated executive employment agreement with its principal executive officer, David Happel (the "Happel Agreement"), an amended and restated executive employment agreement with its principal financial officer, Thierry Chauche (the "Chauche Agreement"), and a second amended and restated executive employment agreement with its named executive officer, Eduardo Bruno Martins, M.D., D.Phil. (the "Martins Agreement", together with the Happel Agreement and the Chauche Agreement, the "Amended Agreements"). Capitalized terms as used herein are defined in the respective Amended Agreements.

Happel Agreement

The Happel Agreement provides that, upon a termination of Mr. Happel's employment without Cause by the Company or resignation for Good Reason by Mr. Happel, in each case, on or within 12 months after the occurrence of the first event constituting a Change in Control, Mr. Happel is entitled to receive: (i) the sum of (A) 24 months of his base salary; plus (B) an amount equal to 24 months of his Target Bonus plus (C) his Target Bonus for the then-current year, prorated to reflect the number of days Mr. Happel worked at the Company during the applicable year; (ii) if Mr. Happel elects coverage under Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (or equivalent state law) ("COBRA"), the Company shall pay to the group health plan provider or COBRA provider a monthly payment equal to both the monthly employee and the monthly employer contribution that the Company would have made to provide health insurance to Mr. Happel if Mr. Happel had remained employed by the Company until the earliest of (A) the 24 month anniversary of the date of Mr. Happel's termination; (B) the date Mr. Happel becomes eligible for group medical plan benefits under any other employer's group medical plan; or (C) the cessation of Mr. Happel's health continuation rights under COBRA; (iii) all stock options and other stock-based awards held by Mr. Happel that are subject vesting shall immediately accelerate and become fully vested and exercisable or nonforfeitable; and (iv) all stock options held by Mr. Happel that are vested as of the date of Mr. Happel's termination of employment shall remain exercisable until the earlier of the date that is 12 months following the date of Mr. Happel's termination or the expiration date of such stock option.

Chauche Agreement

The Chauche Agreement provides that, upon a termination of Mr. Chauche's employment without Cause by the Company or resignation for Good Reason by Mr. Chauche, in each case, on or within 12 months after the occurrence of the first event constituting a Change in Control, Mr. Chauche is entitled to receive: (i) the sum of (A) 15 months of his base salary; plus (B) an amount equal to 15 months of his Target Bonus; plus (C) his Target Bonus for the then-current year, prorated to reflect the number of days Mr. Chauche worked at the Company during the applicable year; (ii) if Mr. Chauche elects coverage under COBRA, the Company shall pay to the group health plan provider or COBRA provider a monthly payment equal to both the monthly employee and the monthly employer contribution that the Company would have made to provide health insurance to Mr. Chauche if he had remained employed by the Company until the earliest of (A) the 15 month anniversary of the date of Mr. Chauche's termination; (B) the date Mr. Chauche become eligible for group medical plan benefits under any other employer's group medical plan; or (C) the cessation of Mr. Chauche's health continuation rights under COBRA; (iii) all stock options and other stock-based awards held by Mr. Chauche that are subject vesting shall immediately accelerate and become fully vested and exercisable or nonforfeitable; and (iv) all stock options held by Mr. Chauche that are vested as of the date of Mr. Chauche's termination of employment shall remain exercisable until the earlier of the date that is 12 months following the date of Mr. Chauche's termination or the expiration date of such stock option.

Sagimet Biosciences Inc. published this content on June 10, 2025, and is solely responsible for the information contained herein. Distributed via SEC EDGAR on June 10, 2025 at 21:17 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at support@pubt.io